A Randomized Control Trial Phase (IIIa) Unicentric, Placebo Controlled, Double-Blinded Efficacy and Safety of Topical Alendronic Acid on Alveolar Bone Remodeling After Tooth Extraction

The purpose of the study is to determine the efficacy and safety of the effects of a topical medication on bone remodeling after dental extraction, in order to establish whether such treatment can be a new therapeutic option for said pathology. The participation of 60 patients is expected, who will be divided randomly in equal proportions into two groups. Treatment groups: Group A (30 patients): medication administered topically. Group B (30 patients): placebo with characteristics equal to the drug under investigation.

Inclusion Criteria:Provide signed and dated informed consent form.Overall, healthy patients that qualify for oral surgery (ASA I and II).Male and female patients 18-90 (inclusive) years of age.Requiring extraction of 1 tooth (maxillary or mandibular).Stable post-extraction socket walls with at least 4 walls.Adequate oral hygiene: plaque index < 25% before the surgery.Non-smoker or smoker of <10 cigarettes per day.Able to follow the instructions and able to meet the follow-ups.Healthy or controlled periodontal disease.Exclusion Criteria:Patients who do not agree with informed consent.Male and female patients are not 18-90 (inclusive) years of age. Patients taking medication that can interfere with the treatment such as Calcium Carbonate or Vitamin D.Untreated periodontal disease.Presence of dehiscence and/or fenestration at buccal plate of the extraction tooth/teeth.Patient who will need guided bone regeneration (GBR) or Block Regeneration after the extraction.History of head and/or neck radiation.History of chemotherapy in the five years prior of the surgery.Non controlled Diabetes.Chronic corticoids medication that may influence healing and/or osseointegration.Smoker of >10 cigars per day.Pregnant womanAlcohol or drugs.Patient going under bisphosphonates treatment or taking Denosumab (Prolia®).Patient with diagnosed osteoporosis, hypocalcemia, hypersensibility to alendronic acid or any of the excipients of Soludronate®.